Pharmsynthez Past Earnings Performance
Past criteria checks 0/6
Pharmsynthez has been growing earnings at an average annual rate of 64.4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 90.9% per year.
Key information
64.4%
Earnings growth rate
65.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 90.9% |
| Return on equity | -89.6% |
| Net Margin | -148.4% |
| Last Earnings Update | 30 Jun 2021 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Pharmsynthez makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 21 | 451 | -670 | 267 | 39 |
| 31 Mar 21 | 411 | -597 | 270 | 42 |
| 31 Dec 20 | 372 | -525 | 274 | 46 |
| 30 Sep 20 | 304 | -1,202 | 239 | 31 |
| 30 Jun 20 | 236 | -1,879 | 205 | 15 |
| 31 Mar 20 | 264 | -1,845 | 225 | 11 |
| 31 Dec 19 | 291 | -1,812 | 246 | 6 |
| 30 Sep 19 | 367 | -942 | 301 | 38 |
| 30 Jun 19 | 442 | -72 | 356 | 70 |
| 31 Mar 19 | 396 | -245 | 380 | 70 |
| 31 Dec 18 | 349 | -418 | 404 | 70 |
| 30 Sep 18 | 412 | 1,254 | 113 | -35 |
| 30 Jun 18 | 480 | 762 | 225 | 96 |
| 31 Mar 18 | 599 | 202 | 316 | 96 |
| 31 Dec 17 | 719 | -358 | 406 | 96 |
| 30 Sep 17 | 768 | -2,591 | 770 | 365 |
| 30 Jun 17 | 812 | -2,660 | 731 | 399 |
| 31 Mar 17 | 736 | -1,651 | 595 | 399 |
| 31 Dec 16 | 661 | -642 | 459 | 399 |
| 30 Sep 16 | 489 | -101 | 372 | 200 |
| 30 Jun 16 | 317 | 441 | 285 | 0 |
| 31 Mar 16 | 344 | 43 | 317 | 0 |
| 31 Dec 15 | 371 | -355 | 350 | 0 |
Quality Earnings: LIFE is currently unprofitable.
Growing Profit Margin: LIFE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LIFE's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LIFE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LIFE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: LIFE has a negative Return on Equity (-89.65%), as it is currently unprofitable.